Fractyl has broadened its U.S. patent position around Revita, an endoscopic duodenal mucosal resurfacing system that uses controlled hydrothermal ablation, as it prepares a De Novo submission to the FDA for weight maintenance after GLP-1 discontinuation. The new grants cover single-use catheter design and a thermal dosing method that independently regulates heated and cooling fluids, bringing the portfolio to 39 granted U.S. patents. The clinical target is weight regain following pharmacologic therapy, a persistent failure point in metabolic treatment.
Key Points
- New patents cover catheter design and dual-fluid thermal dosing control
- Portfolio reaches 39 granted U.S. patents, 50-plus international
- De Novo submission targets post-GLP-1 weight maintenance after REMAIN-1 results
Longevity Analysis
Weight regain after GLP-1 withdrawal exposes the limits of continuous pharmacologic suppression: when the drug stops, the underlying signaling in the duodenal lining reasserts itself. Resurfacing the duodenal mucosa attempts to reset that interface directly, restoring the gut's hormonal conversation with glucose handling and energy regulation rather than overriding it indefinitely. For metabolic health across decades, the distinction between a durable single intervention and permanent dependence on injectable therapy carries real consequences for adherence, cost, and the long-term integrity of lean mass.
Original published by LT Wire.